Research

Mixed

GLP-1 receptor agonists for obesity treatment cause significant loss of lean body mass (approximately 38% of total weight loss) and muscle mass, increasing the risk of sarcopenia and bone loss, particularly in the absence of structured resistance training and adequate protein intake.

If you are taking a GLP-1 medication for weight loss, expect to lose some muscle along with fat. To protect your strength and metabolism, you must prioritize resistance training (weight lifting or bodyweight exercises) and ensure you are eating enough protein. Without these steps, you risk losing significant muscle mass, which can happen with any rapid weight loss method.

GoodSupportsHIGH confidence
In the STEP 1 trial, of the average 13.6-kg–weight reduction, 8.3 kg (62%) was fat mass and 5.3 kg (38%) was lean body mass (including muscle and other nonfat tissues)... Because muscle mass is about half of lean body mass, this corresponds to ~20% of total weight reduction being muscle loss.
Dariush Mozaffarian et al. · American Journal of Clinical Nutrition · 2025

Why this rating

Based on data from landmark randomized controlled trials (STEP 1, SURMOUNT 1) cited in the advisory.

Source

Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society

Dariush Mozaffarian et al. · American Journal of Clinical Nutrition · 2025

DOI 10.1016/j.ajcnut.2025.04.023

clinical_guidelineCited 69×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →